AXLRx Book a callCommission

Big Pharma · Immunology

Eli Lilly — Immunology

Eli Lilly across Immunology: the full competitive set, and the 2 AXLRx reports mapping the competitive, patient-flow and payer picture — each scoped to a single asset and cited to a live source.

Commission a Eli Lilly report

By therapy area

Therapy area All areas NeurologyImmunologyMetabolic

Market All United States

AXLRx reports featuring Eli Lilly — Immunology

CI · Immunology · CI Team · Launch Lead US Atopic Dermatitis Competitive Intelligence Dupilumab's 70% biologic share against JAK step-edits. A two-tier US payer landscape for IL-4Ra biologics and oral JAKs. US · In-Market · Read report → CI · Immunology · CI Team · Launch Lead US Plaque Psoriasis Competitive Intelligence Six mechanisms now compete for moderate-to-severe plaque psoriasis in the US, and the efficacy bar has moved from PASI 75 to PASI 90. IL-17A, dual IL-17A/F, IL-23p19, IL-12/23, TNF and oral TYK2 all hold ground. US · In-Market · Read report →